Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines, a commercial-stage biotechnology company specializing in oncology therapeutics, is positioned for sustained growth, bolstered by its leading drug, Brukinsa, which holds a significant share of over 60% in company revenue and has strong market preference among key opinion leaders. The company's unique CRO-free strategy enhances its operational efficiency, allowing it to run global trials independently, which may lead to improved financial performance and a path toward positive free cash flow by 2025. Projections indicate robust annual growth exceeding 40% and an estimated peak sales potential of approximately $7.1 billion by 2034, underscoring BeOne's competitive advantage and favorable market dynamics.

Bears say

BeOne Medicines faces a negative outlook primarily due to significant risks tied to its reliance on Brukinsa, which constitutes over 60% of the company's revenue; any pressures on this key product could lead to substantial downside. Additionally, the company confronts challenges such as slower-than-expected uptake of its commercial products, potential delays in clinical trials, and risks associated with its crowded oncology market, where competition for next-generation therapies is intense. Furthermore, the perception of geopolitical risks related to its Chinese origins, combined with considerable cash burn on its pipeline that may not yield marketable drugs, threatens the overall financial stability and competitive positioning of BeOne Medicines.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $374.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $374.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.